Actively Recruiting
T-cell Therapy in Patients With PML
Led by Hannover Medical School · Updated on 2026-02-12
23
Participants Needed
6
Research Sites
90 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in this study. The sponsor wants to find out whether the IMP is safe, influences the neurological status and improves the quality of the life of patients . It is to be investigated whether the IMP can be used to treat the disease and whether it could have an advantage over the standard therapy in terms of survival rate.
CONDITIONS
Official Title
T-cell Therapy in Patients With PML
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older with PML diagnosed within 60 days before screening and associated with lymphoproliferative diseases, immunosuppressive therapy, or lymphopenia
- Signed written informed consent from the participant or legal representative
- Detection of HPyV-2 in cerebrospinal fluid by PCR or in brain biopsy
You will not qualify if you...
- PML caused by HIV or natalizumab
- PML occurring within 5 years after hematopoietic stem-cell transplantation or CAR T cell therapy, or resulting from chronic lymphocytic leukemia (CLL)
- Inability to follow the study protocol independently or with support
- Pregnancy or breastfeeding
- Current chemotherapy treatment
- Treatment with immune checkpoint inhibition therapy within 2 weeks before screening
- Severe infections other than PML (e.g., sepsis, pneumonia)
- Hypersensitivity to any medication components used in the study
- Inability to undergo MRI examination (e.g., incompatible implants, claustrophobia)
- Participation in another clinical trial with investigational drugs or devices within 30 days prior to enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
LMU Klinikum Campus Großhadern
München, Bavaria, Germany, 81377
Not Yet Recruiting
2
Universitätsklinikum Marburg
Marburg, Hesse, Germany
Not Yet Recruiting
3
Hannover Medical School
Hanover, Lower Saxony, Germany, 30625
Actively Recruiting
4
Universitätsklinikum Düsseldorf
Düsseldorf, North Rhine-Westphalia, Germany, 40225
Not Yet Recruiting
5
Universitätsklinikum Essen
Essen, North Rhine-Westphalia, Germany, 45147
Not Yet Recruiting
6
Universitätsklinikum Schleswig-Holstein
Kiel, Schleswig-Holstein, Germany, 24105
Not Yet Recruiting
Research Team
T
Thomas Skripuletz, Prof. Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here